Differences in various efficiency metrics were modest, but “minutes matter in stroke,” Shyam Prabhakaran says.

T-FLAVOR investigators compared tenecteplase with low-dose alteplase in stroke patients scheduled for endovascular therapy (EVT). The trial notably took place in Japanese patients, believed to be more ...

Please provide your email address to receive an email when new articles are posted on . Administration of low-dose IV tenecteplase in the 4.5 to 24 hours after stroke symptom onset seemed to be safe ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

A study investigating a high dose (0.4 mg/kg) of the bolus thrombolytic tenecteplase in the treatment of patients with moderate to severe acute ischemic stroke was stopped prematurely because of ...

Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

Tenecteplase (TNKase) appeared feasible for thrombolysis in acute ischemic stroke in patients presenting up to 24 hours after symptom onset, a phase II trial suggested. The typical 0.25 mg/kg dose of ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase ...

Standard-dose tenecteplase (TNKase) beat low-dose alteplase as a bridge to stroke thrombectomy in bleeding-prone patients, a Japanese trial found. Early reperfusion outcomes significantly favored ...